Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

4th HIV Research for Prevention Conference (HIVR4P // Virtual)—Rapid Recap

January 27-28 and February 3-4, 2021
Hear insights from Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, on some of the most important new data reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, implantable options, multipurpose prevention strategies, and key aspects of PrEP implementation
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Released: February 18, 2021

In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.  

Presenter:

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD 
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Released: March 1, 2021

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies, and more

Kenneth Mayer, MD Released: February 25, 2021

Commentary from Dr. Kenneth Mayer on data from HIVR4P 2021 on immunoprophylaxis and multipurpose prevention as PrEP, from Clinical Care Options (CCO)

Kenneth Mayer, MD Released: February 18, 2021

Expert selections of the most important data from HIVR4P 2021 Virtual, including PrEP clinical trials, implementation strategies and more, from CCO

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Kenneth Mayer, MD Released: February 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue